Taking a low-dose aspirin once a day does not reduce the risk of thinking and memory problems caused by mild cognitive impairment or probable Alzheimer’s disease, nor does it slow the rate of cognitive decline, according to a large study published in the March 25, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Aspirin has anti-inflammatory properties and also thins the blood. For years, doctors have been prescribing low-dose aspirin for some people to reduce their risk of heart disease and stroke. However, there are also possible risks to taking aspirin, including bleeding in the brain, so guidance from a doctor is important.
Because aspirin can be beneficial to the heart, researchers have hypothesized, and smaller previous studies have suggested, that it may also be beneficial to the brain, possibly reducing the risk of dementia by reducing inflammation, minimizing small clots, or by preventing the narrowing of blood vessels within the brain.
“Worldwide, an estimated 50 million people have some form of dementia, a number that is expected to grow as the population increases, so the scientific community is eager to find a low-cost treatment that may reduce a person’s risk,” said study author Joanne Ryan, Ph.D., of Monash University’s School of Public Health in Melbourne, Australia. “Unfortunately, our large study found that a daily low-dose aspirin provided no benefit to study participants at either preventing dementia or slowing cognitive decline.”
The study involved 19,114 people who did not have dementia or heart disease. A majority of participants were age 70 or older. They took thinking and memory tests at the start of the study as well as during follow-up visits.
Half of the people were given daily 100 milligram low-dose aspirin while the other half were given a daily placebo. They were followed for an average of 4.7 years, with annual in-person examinations.
Over the course of the study, 575 people developed dementia.
Researchers found no difference between those who took aspirin and those who took placebo in the risk of developing mild cognitive impairment, dementia, or probable Alzheimer’s disease. There was also no difference in the rate of cognitive change over time.
“While these results are disappointing, it is possible that the length of just under five years for our study was not long enough to show possible benefits from aspirin, so we will continue to examine its potential longer-term effects by following up with study participants in the coming years,” said Ryan.
A limitation of the study was that only relatively healthy people were enrolled, and such a population may benefit less from aspirin than the general population.
Reference: “Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline” by Joanne Ryan, Elsdon Storey, Anne M. Murray, Robyn L. Woods, Rory Wolfe, Christopher M. Reid, Mark R. Nelson, Trevor T.J. Chong, Jeff D. Williamson, Stephanie A. Ward, Jessica E. Lockery, Suzanne G. Orchard, Ruth Trevaks, Brenda Kirpach, Anne B. Newman, Michael E. Ernst, John J. McNeil and Raj C. Shah, 25 March 2020, Neurology.
DOI: 10.1212/WNL.0000000000009277
The study was supported by the National Institute on Aging, the National Cancer Institute and the National Institutes of Health in the United States, the Australian National Health and Medical Research Council, Monash University and the Victorian Cancer Agency. Bayer, the maker of the drug, provided the trial drug and placebo but had no other role in this trial.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.